COVID-19疫情期间孔源性视网膜脱离的临床表现:历史对照研究
该单中心历史对照研究比较了2020年COVID-19疫情期间50天与2019年同期50天连续就诊的原发性孔源性视网膜脱离(RRD)患者。2020年队列黄斑在位RRD比例显著更低(24.4% vs 49.5%,P=0.001),就诊视力更差、症状出现1天内就诊者更少、原发性增生性玻璃体视网膜病变(PVR)更多。
要点
- 疫情期间RRD患者黄斑在位比例由49.5%降至24.4%,就诊时视力更差。
- 仅19.5%的患者在症状出现1天内就诊,低于此前的36.9%。
- 2020年队列原发性PVR比例升高(13.4% vs 4.5%)。
核心结论
- 2020年COVID-19疫情期间的原发性RRD患者较少表现为黄斑在位,更常延迟就诊,视力更差且PVR更多。
研究设计与样本
- 单中心、连续病例系列加历史对照研究,比较2020年3月9日至4月27日50天与2019年3月4日至4月22日50天美国连续就诊的原发性RRD患者。
- 2020年队列82例,2019年对照队列111例,比较人口学变量与临床表现,并用多因素logistic回归分析黄斑在位状态的预测因素。
主要发现
- 2020年队列黄斑在位RRD为20/82例(24.4%),2019年队列为55/111例(49.5%),P=0.001。
- 2020年就诊中位视力为1.00 logMAR(Snellen约20/200),2019年为0.48 logMAR(Snellen约20/60),P=0.008。
- 症状出现1天内就诊者2020年为16/80例(19.5%),2019年为41/106例(36.9%),P=0.005。
- 原发性PVR在2020年为11/82例(13.4%),2019年为5/111例(4.5%),P=0.03。
- 多因素分析中,2020年队列黄斑在位的独立预测因素为较年轻年龄(P=0.03)和已建立就诊关系患者(P=0.02)。
关键数值与推荐
- 主要结局为就诊时黄斑在位RRD的比例;次要结局包括视力、症状持续时间、症状出现1天内就诊比例及原发性PVR。
临床怎么用
- 提示在公共卫生事件期间需加强RRD急症就诊宣教,减少就诊延迟以保护黄斑功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the effect of the coronavirus disease 2019 (COVID-19) pandemic on the clinical presentation of acute, primary rhegmatogenous retinal detachment (RRD). DESIGN: Single-center, consecutive case series with historical controls. PARTICIPANTS: Consecutive patients seeking treatment for primary RRD in a 50-day period during the COVID-19 pandemic (March 9-April 27, 2020) and the corresponding 50-day period during the previous year (March 4-April 22, 2019) in the United States. METHODS: The cohorts were compared to assess demographic variables and clinical presentations. Multivariate logistic regression was used to identify factors predictive of presenting macular attachment status. MAIN OUTCOME MEASURES: The primary outcome was the proportion of patients with macula-on RRD at presentation. Secondary outcomes included visual acuity (VA), duration of symptoms before presentation, proportion seeking treatment within 1 day of symptom onset, and presence of primary proliferative vitreoretinopathy (PVR). RESULTS: Eighty-two patients were included in the 2020 cohort compared with 111 patients in the 2019 primary control cohort. Demographic factors were similar between the groups. Significantly fewer patients demonstrated macula-on RRD in the 2020 cohort (20/82 patients [24.4%]) than in the 2019 cohort (55/111 patients [49.5%]; P = 0.001). Patients in the 2020 cohort showed worse median VA at presentation (1.00 logarithm of the minimum angle of resolution [logMAR; Snellen equivalent, 20/200] in 2020 vs. 0.48 logMAR [Snellen equivalent, 20/60] in 2019; P = 0.008), fewer patients sought treatment within 1 day of symptoms (16/80 patients [19.5%] in 2020 vs. 41/106 patients [36.9%] in 2019; P = 0.005), and a greater proportion demonstrated primary PVR (11/82 patients [13.4%] in 2020 vs. 5/111 patients [4.5%] in 2019; P = 0.03). In multivariate analysis, younger age (P = 0.03) and established patient status (P = 0.02) were independent predictors of macula-on status in the 2020 cohort. CONCLUSIONS: Patients with primary RRD during the 2020 COVID-19 pandemic were less likely to have macula-on disease and more likely to delay seeking treatment and to show worse vision and PVR.
引用
- Patel LG, Peck T, Starr MR, et al. Clinical Presentation of Rhegmatogenous Retinal Detachment during the COVID-19 Pandemic: A Historical Cohort Study. Ophthalmology. 2020. PMID: 33058938. doi:10.1016/j.ophtha.2020.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。